Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Outstanding (2016 - 2025)

Vistagen Therapeutics' Shares Outstanding history spans 12 years, with the latest figure at $39.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 39.91% year-over-year to $39.6 million; the TTM value through Dec 2025 reached $39.6 million, up 39.91%, while the annual FY2025 figure was $29.0 million, 7.29% up from the prior year.
  • Shares Outstanding for Q4 2025 was $39.6 million at Vistagen Therapeutics, up from $38.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $196.6 million in Q3 2021 and bottomed at $500000.0 in Q2 2021.
  • The 4-year median for Shares Outstanding is $27.1 million (2024), against an average of $35.4 million.
  • The largest YoY upside for Shares Outstanding was 16416.58% in 2021 against a maximum downside of 56.91% in 2021.
  • A 4-year view of Shares Outstanding shows it stood at $500000.0 in 2021, then skyrocketed by 5305.95% to $27.0 million in 2023, then rose by 4.78% to $28.3 million in 2024, then soared by 39.91% to $39.6 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Shares Outstanding are $39.6 million (Q4 2025), $38.9 million (Q3 2025), and $29.3 million (Q2 2025).